Cargando…
Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases
The use of immune checkpoint inhibitors (ICIs) delivered great and new possibilities in modern treatment of many types of cancers. This therapy based on blockade of such molecules as CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1 (programmed cell death receptor type 1), or PD-1 ligand (PD-...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710966/ https://www.ncbi.nlm.nih.gov/pubmed/33330040 http://dx.doi.org/10.3389/fonc.2020.568081 |
_version_ | 1783618043959574528 |
---|---|
author | Kubiatowski, Tomasz Nicoś, Marcin Krawczyk, Paweł |
author_facet | Kubiatowski, Tomasz Nicoś, Marcin Krawczyk, Paweł |
author_sort | Kubiatowski, Tomasz |
collection | PubMed |
description | The use of immune checkpoint inhibitors (ICIs) delivered great and new possibilities in modern treatment of many types of cancers. This therapy based on blockade of such molecules as CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1 (programmed cell death receptor type 1), or PD-1 ligand (PD-L1) brings a new hope for patients with non-small cell lung cancer (NSCLC), melanoma, or head and neck squamous carcinoma. Efficacy of immunotherapy was proven in many clinical trials. Unfortunately, ICIs treatment was not addressed to the patients with preexisting allogeneic transplants or autoimmune diseases mainly due to high risk of transplant rejection, exacerbation of autoimmune diseases, and risk of serious toxicity. However, it is possible to receive anti-tumor response to ICIs treatment avoiding graft rejection by adjusting the immunosuppression. Obviously, it depends on the type of transplants: the use of immunotherapy is usually possible in kidney or corneal recipients, but it could be difficult in patients with liver and heart transplant. Therefore, the development of biomarkers for tumor response and transplant rejection in ICIs treated patients is essential. Data coming from published literature support the possibilities of using ICIs in patients with preexisting autoimmune diseases who undergoing proper management of side effects of immunotherapy or when the potential benefits of such treatment outweigh the potential risks. This depends on the type of autoimmune disease and may be difficult or not feasible in patients with systemic lupus erythematosus or systemic sclerosis. Therefore, it may be appropriate to include cancer patients with preexisting autoimmune disease or with allogeneic transplants in clinical trials using immunotherapy when no other effective cancer treatment options exist. |
format | Online Article Text |
id | pubmed-7710966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77109662020-12-15 Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases Kubiatowski, Tomasz Nicoś, Marcin Krawczyk, Paweł Front Oncol Oncology The use of immune checkpoint inhibitors (ICIs) delivered great and new possibilities in modern treatment of many types of cancers. This therapy based on blockade of such molecules as CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1 (programmed cell death receptor type 1), or PD-1 ligand (PD-L1) brings a new hope for patients with non-small cell lung cancer (NSCLC), melanoma, or head and neck squamous carcinoma. Efficacy of immunotherapy was proven in many clinical trials. Unfortunately, ICIs treatment was not addressed to the patients with preexisting allogeneic transplants or autoimmune diseases mainly due to high risk of transplant rejection, exacerbation of autoimmune diseases, and risk of serious toxicity. However, it is possible to receive anti-tumor response to ICIs treatment avoiding graft rejection by adjusting the immunosuppression. Obviously, it depends on the type of transplants: the use of immunotherapy is usually possible in kidney or corneal recipients, but it could be difficult in patients with liver and heart transplant. Therefore, the development of biomarkers for tumor response and transplant rejection in ICIs treated patients is essential. Data coming from published literature support the possibilities of using ICIs in patients with preexisting autoimmune diseases who undergoing proper management of side effects of immunotherapy or when the potential benefits of such treatment outweigh the potential risks. This depends on the type of autoimmune disease and may be difficult or not feasible in patients with systemic lupus erythematosus or systemic sclerosis. Therefore, it may be appropriate to include cancer patients with preexisting autoimmune disease or with allogeneic transplants in clinical trials using immunotherapy when no other effective cancer treatment options exist. Frontiers Media S.A. 2020-11-19 /pmc/articles/PMC7710966/ /pubmed/33330040 http://dx.doi.org/10.3389/fonc.2020.568081 Text en Copyright © 2020 Kubiatowski, Nicoś and Krawczyk http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kubiatowski, Tomasz Nicoś, Marcin Krawczyk, Paweł Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title | Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title_full | Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title_fullStr | Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title_full_unstemmed | Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title_short | Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases |
title_sort | lung cancer immunotherapy in transplant patients and in patients with autoimmune diseases |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710966/ https://www.ncbi.nlm.nih.gov/pubmed/33330040 http://dx.doi.org/10.3389/fonc.2020.568081 |
work_keys_str_mv | AT kubiatowskitomasz lungcancerimmunotherapyintransplantpatientsandinpatientswithautoimmunediseases AT nicosmarcin lungcancerimmunotherapyintransplantpatientsandinpatientswithautoimmunediseases AT krawczykpaweł lungcancerimmunotherapyintransplantpatientsandinpatientswithautoimmunediseases |